Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
ARGX
ARGX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ARGX News
Argenx SE Rated as One of the Best Growth Stocks for the Next Decade
Feb 04 2026
Yahoo Finance
China SXT Pharmaceuticals (SXTC) Closes $10 Million Offering, Stock Rises 17.4%
Jan 14 2026
NASDAQ.COM
Argenx (ARGX) Receives FDA Priority Review for Vyvgart Expansion Application
Jan 13 2026
seekingalpha
Argenx's VYVGART Receives FDA Priority Review for First Treatment of AChR-Ab Seronegative MG
Jan 13 2026
NASDAQ.COM
Argenx (ARGX) Files Supplemental Biologics License Application for Vyvgart
Jan 13 2026
Yahoo Finance
argenx Submits VYVGART sBLA for FDA Priority Review, Target Date May 10, 2026
Jan 13 2026
Globenewswire
argenx Files for Priority Review of VYVGART for gMG Treatment with FDA
Jan 13 2026
Newsfilter
argenx Reports $4.15B in 2025 Net Sales, Up 90% Year-over-Year
Jan 12 2026
NASDAQ.COM
argenx Reports $4.15 Billion in 2025 Global Product Net Sales, Up 90%
Jan 12 2026
Globenewswire
argenx Reports $4.15 Billion in Global Product Net Sales for 2025, Up 90%
Jan 12 2026
Newsfilter
argenx Reports $4.15 Billion in 2025 Global Product Sales, Up 90%
Jan 12 2026
Yahoo Finance
AbbVie Upgraded Price Target to $269 Despite 4% Stock Drop
Jan 06 2026
Benzinga
argenx CEO Tim Van Hauwermeiren to Present at J.P. Morgan Healthcare Conference on January 12, 2026
Jan 06 2026
Globenewswire
argenx Transitions CEO Role to Karen Massey, Tim Van Hauwermeiren Becomes Chairman
Jan 05 2026
Globenewswire
argenx Appoints Karen Massey as New CEO, Transitioning Tim Van Hauwermeiren to Chairman
Jan 05 2026
Yahoo Finance
Biotech Stocks Surge in 2025 with $30.9 Billion M&A Wave
Dec 31 2025
Benzinga
Show More News
